Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4 Purity >98.0% (HPLC) Lenvatinib Mesylate Intermediate Factory
Ugavi wa Kemikali wa Ruifu Lenvatinib Mesylate Inapatana na Usafi wa Juu
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinil Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Jina la Kemikali | Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate |
Visawe | Uchafu wa Lenvatinib 47;4-Chloro-7-Methoxyquinoline-6-Carboxylic Acid Methyl Ester;4-Chloro-7-Methoxy-6-Quinolinecarboxylic Acid Methyl Ester;Lenvaint-D |
Nambari ya CAS | 205448-66-4 |
Nambari ya CAT | RF-PI1970 |
Hali ya Hisa | Katika Hisa, Uzalishaji Umeongezeka Hadi Tani |
Mfumo wa Masi | C12H10ClNO3 |
Uzito wa Masi | 251.67 |
Kuchemka | 377.4±37.0℃ |
Msongamano | 1.320±0.06 g/cm3 |
Chapa | Ruifu Chemical |
Kipengee | Vipimo |
Mwonekano | Nyeupe-Nyeupe hadi Njano Imara |
1 H NMR Spectrum | Sambamba na Muundo |
Njia ya Usafi / Uchambuzi | >98.0% (HPLC) |
Kupoteza kwa Kukausha | <1.00% |
Jumla ya Uchafu | <2.00% |
Kiwango cha Mtihani | Kiwango cha Biashara |
Matumizi | Uchafu wa kati/Uchafu wa Lenvatinib Mesylate (CAS: 857890-39-2) |
Kifurushi: Chupa, begi ya karatasi ya Alumini, Ngoma ya 25kg/Cardboard, au kulingana na mahitaji ya mteja
Hali ya Uhifadhi:Hifadhi kwenye vyombo vilivyofungwa mahali pa baridi na kavu;Kinga kutoka kwa mwanga na unyevu
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate (CAS: 205448-66-4) ni ya kati ya Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib ni dawa ya saratani ya tezi iliyotengenezwa na Shirika la Eisai la Japani (Kanuni: E7080), inayomilikiwa na kizuizi cha tyrosine kinase (RTK) yenye vipokezi vingi na inaweza kuzuia shughuli ya kinase ya vipokezi vya ukuaji wa mishipa ya fahamu R1 (FLT1), VEG-FR2 (KDR), R3 (FLT4).Lenvatinib pia inaweza kuzuia ushiriki wa RTK nyingine katika angiojenesisi ya patholojia, ukuaji wa uvimbe, na kuendelea kwa saratani isipokuwa kazi zao za kawaida za seli ikiwa ni pamoja na vipokezi vya ukuaji wa fibroblast (FGF) FGFR1, 2, 3, na 4;kipokezi cha kipengele cha ukuaji kinachotokana na chembe (PDGFR [alpha]), KIT, na RET.[Dalili]: Lenvatinib inafaa kwa ajili ya matibabu ya wagonjwa wa saratani ya tezi ya tezi ya kurudi tena au aina ya metastasis, aina ya maendeleo na aina tofauti ya iodini-refractory ya mionzi.